406 related articles for article (PubMed ID: 29203668)
1. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.
Stone ML; Chiappinelli KB; Li H; Murphy LM; Travers ME; Topper MJ; Mathios D; Lim M; Shih IM; Wang TL; Hung CF; Bhargava V; Wiehagen KR; Cowley GS; Bachman KE; Strick R; Strissel PL; Baylin SB; Zahnow CA
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10981-E10990. PubMed ID: 29203668
[TBL] [Abstract][Full Text] [Related]
2. Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
Moufarrij S; Srivastava A; Gomez S; Hadley M; Palmer E; Austin PT; Chisholm S; Diab N; Roche K; Yu A; Li J; Zhu W; Lopez-Acevedo M; Villagra A; Chiappinelli KB
Sci Rep; 2020 Feb; 10(1):3470. PubMed ID: 32103105
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a
McDonald JI; Diab N; Arthofer E; Hadley M; Kanholm T; Rentia U; Gomez S; Yu A; Grundy EE; Cox O; Topper MJ; Xing X; Strissel PL; Strick R; Wang T; Baylin SB; Chiappinelli KB
Cancer Res; 2021 Oct; 81(20):5176-5189. PubMed ID: 34433584
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Turner TB; Meza-Perez S; Londoño A; Katre A; Peabody JE; Smith HJ; Forero A; Norian LA; Straughn JM; Buchsbaum DJ; Randall TD; Arend RC
Oncotarget; 2017 Jul; 8(27):44159-44170. PubMed ID: 28498806
[TBL] [Abstract][Full Text] [Related]
5. DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.
Travers M; Brown SM; Dunworth M; Holbert CE; Wiehagen KR; Bachman KE; Foley JR; Stone ML; Baylin SB; Casero RA; Zahnow CA
Cancer Res; 2019 Jul; 79(13):3445-3454. PubMed ID: 31088836
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D
Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
[TBL] [Abstract][Full Text] [Related]
8. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
9. Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer.
McCaw TR; Goel N; Brooke DJ; Katre AA; Londoño AI; Smith HJ; Randall TD; Arend RC
Cancer Med; 2021 Jan; 10(2):709-717. PubMed ID: 33369199
[TBL] [Abstract][Full Text] [Related]
10. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer.
Gomez S; Cox OL; Walker RR; Rentia U; Hadley M; Arthofer E; Diab N; Grundy EE; Kanholm T; McDonald JI; Kobyra J; Palmer E; Noonepalle S; Villagra A; Leitenberg D; Bollard CM; Saunthararajah Y; Chiappinelli KB
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36343976
[TBL] [Abstract][Full Text] [Related]
12. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
13. Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells.
Liu M; Thomas SL; DeWitt AK; Zhou W; Madaj ZB; Ohtani H; Baylin SB; Liang G; Jones PA
Cancer Res; 2018 Oct; 78(20):5754-5766. PubMed ID: 30185548
[TBL] [Abstract][Full Text] [Related]
14. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract][Full Text] [Related]
15. Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.
Wang L; Amoozgar Z; Huang J; Saleh MH; Xing D; Orsulic S; Goldberg MS
Cancer Immunol Res; 2015 Sep; 3(9):1030-41. PubMed ID: 26056145
[TBL] [Abstract][Full Text] [Related]
16. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Mazzone R; Zwergel C; Mai A; Valente S
Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
Grabosch S; Bulatovic M; Zeng F; Ma T; Zhang L; Ross M; Brozick J; Fang Y; Tseng G; Kim E; Gambotto A; Elishaev E; P Edwards R; Vlad AM
Oncogene; 2019 Mar; 38(13):2380-2393. PubMed ID: 30518877
[TBL] [Abstract][Full Text] [Related]
18. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
[TBL] [Abstract][Full Text] [Related]
19. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
[TBL] [Abstract][Full Text] [Related]
20. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.
West AC; Mattarollo SR; Shortt J; Cluse LA; Christiansen AJ; Smyth MJ; Johnstone RW
Cancer Res; 2013 Dec; 73(24):7265-76. PubMed ID: 24158093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]